G20 G30 E88.9
Conditions
Interventions
Group 1: People with Parkinson disease
Participation in the study consists of two visits. On visit 1, inclusion in the study takes place after the inclusion and exclusion criteria have been checked.
duration approx. 5 h). Optionally, subjects could participate in two further study days, on which a 3-h mixed-meal tolerance test (MMTT) or 3-h fasting state observation are conducted (duration approx
Sponsors
Klinik für Parkinson, Schlaf- und Bewegungsstörungen, Zentrum für Neurologie, Universitätsklinikum Bonn
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: • BMI 18,5-39,9 kg/m² • Non-smoker (for at least 3 months) written declaration of consent for participation in the study. • Diagnosis Parkinson disease or Alzheimer disease PD cohort: • PD based on clinical diagnosis according to Brain Bank criteria(Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNNP 1992;55:181-184.) • Hoehn & Yahr stadium 1-3 AD cohort • Clinical and biomarker-based diagnosis with Alzheimer's pathology based on typical CSF findings Mixed dementia with a vascular component (up to Fazekas II) is permitted.
Exclusion criteria
Exclusion criteria: • Taking medications that affect glucose metabolism • chronic inflammatory bowel or liver diseases • antibiotic therapy 3 weeks before the start of the study • Planned lifestyle changes • regular intake of supplements • drug abuse • participation in another clinical trial simultaneously/in the last 30 days PD cohort: • Atypical PD syndromes • DBS care • severe motor fluctuations AD cohort: • Dementia of unclear origin • Heavy vascular part (Fazekas III)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolic differences | — |
Secondary
| Measure | Time frame |
|---|---|
| intestinal microbiome (composition, diversity), concentration of various intestinal hormones, parameter of intestinal permeability, parameter of glucose and lipid metabolism, parameter of inflammation, neuroinflammation and antioxidative defence, short chain fatty acids (SCFAs), amino acids, serotonin, electrolytes. Further parameters: anthropometrics (body weight, body height, waist and hip ratio, body composition (BodPod), resting energy expenditure (QuarkRMR), cognition, transit time, nutritional behaviour, physical activity, socio-economic status, chronobiology, gynaecological history. Security parameters: small blood count, parameters of renal and hepatic function (GOT, GPT, GGT, bilirubin, uric acid, urea, creatinine). | — |
Countries
Germany
Contacts
Public ContactJanis Bedarf
Klinik für Parkinson, Schlaf- und Bewegungsstörungen, Zentrum für Neurologie, Universitätsklinikum Bonn
Outcome results
None listed